Based on these results, the treatment guidelines recommend one year of adjuvant olaparib for patients with HER2-negative, early-stage BC and gBRCAm who meet the criteria for high recurrence risk as defined in the OlympiA trial enrollment criteria discussed above [90]. This evidence concerns the gene ERBB2 and breast cancer.